---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-23-000008"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:35:48.670572+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AtriCure reports Q4 2022 preliminary revenue $88M (+20% YoY); guides 2023 rev $380-387M

## Summary
- Q4 2022 revenue ~$88M (U.S. $73.9M, intl $14.1M), up 20% YoY.
- FY2022 revenue $330.4M, up 20% YoY; adjusted EBITDA loss ~$4M.
- Adjusted loss per share for FY2022 estimated at $1.10–$1.12.
- 2023 guidance: revenue $380–$387M, growth 15–17%; EBITDA breakeven.
- CEO cites strong demand across product lines; outlook reflects continued momentum.

## SEC filing metadata
- accession: 0001323885-23-000008
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/0001323885-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/atrc-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-23-000008
- JSON: https://secwatch.observer/filing/0001323885-23-000008.json
- Plain text: https://secwatch.observer/filing/0001323885-23-000008.txt

## Key facts
- Earnings Releases
  AtriCure, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $330.4 million, EPS approximately $1.10 to $1.12. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $330.4 million
  - EPS: approximately $1.10 to $1.12
  - Guidance: initiated
  - Result: preliminary results
  source text: Preliminary, unaudited revenue for fourth quarter 2022 is expected to be approximately $88.0 million, reflecting growth of approximately 20% over the fourth quarter of 2021 (21% on a constant currency basis).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/0001323885-23-000008-index.htm
- Earnings Releases
  AtriCure, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $330.4 million, EPS approximately $1.10 to $1.12. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $330.4 million
  - EPS: approximately $1.10 to $1.12
  - Guidance: initiated
  - Result: preliminary results
  source text: Preliminary, unaudited revenue for full year 2022 is expected to be $330.4 million, reflecting growth of approximately 20% over full year 2021 (22% on a constant currency basis).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1323885/000132388523000008/0001323885-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.